I'm Lydia Who, and this is the Fox Business Rundown.

Monday, December 22nd, 2025.

The Eastman Kodak Company is ready for its close-up.

The 130-year-old film company make big moves this year to bulk up its balance sheet and push into a brand new field, pharmaceuticals.

We went back to our core values and our core roots and our core competencies and we put together a plan to utilize this park we have in Rochester and the U.S., right, which is 1,200 acres and a lot of technology.

We put it back to use is what we've been doing.

Kodak completed a pension reversion in November, which unlocked $1 billion.

The funds create a new pension fund, bring debt down to $200 million, and put $300 million in cash on the balance sheet.

The goal now, innovate.

Kodak has always been a chemical company.

Executives are using that expertise to move into pharmaceuticals.

Fox Business recently got a tour with the new FDA registered pharmaceutical manufacturing facility

at Kodak's headquarters in Rochester, New York, where phosphate-buffered saline solution is produced

for use in labs and hospitals. Kodak still makes film. The print business remains the biggest

generator of revenue, but CEO Jim Cotonenza says the days when

Kodak relied on a single product are over, and their pension reversion will help their plans

to grow.

You know, it's a great milestone helps us de-lever the business, but we still have to go out and

execute.

I mean, it's just a natural process.

Jim Kotenza is executive chairman and chief executive officer of Eastman Kodak Company.

But it's great to get that done, get the new one set up for the new employees.

...